Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...
12d
TipRanks on MSNOnco-Innovations Unveils Promising PNKP Inhibitors to Boost ChemotherapyOnco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...
Chemotherapy is a treatment used to kill cancer cells ... anthracyclines and topoisomerase inhibitors. The oncometabolite D-2-HG has been implicated in compromising DNA repair pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results